ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Cannabis Bioscience International Holdings Inc (PK)

Cannabis Bioscience International Holdings Inc (PK) (CBIH)

0.0009
0.0001
( 12.50% )
Updated: 10:33:58

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.0009
Bid
0.0008
Ask
0.0009
Volume
8,578,500
0.0008 Day's Range 0.0009
0.0003 52 Week Range 0.002
Market Cap
Previous Close
0.0008
Open
0.0008
Last Trade
89985
@
0.0009
Last Trade Time
10:54:29
Financial Volume
$ 7,511
VWAP
0.000876
Average Volume (3m)
13,576,690
Shares Outstanding
10,381,749,347
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-0
Revenue
317k
Net Profit
-1.03M

About Cannabis Bioscience International Holdings Inc (PK)

Sector
Coml Physical, Biologcl Resh
Industry
Coml Physical, Biologcl Resh
Headquarters
Centennial, Colorado, USA
Founded
1970
Cannabis Bioscience International Holdings Inc (PK) is listed in the Coml Physical, Biologcl Resh sector of the OTCMarkets with ticker CBIH. The last closing price for Cannabis Bioscience (PK) was $0. Over the last year, Cannabis Bioscience (PK) shares have traded in a share price range of $ 0.0003 to $ 0.002.

Cannabis Bioscience (PK) currently has 10,381,749,347 shares outstanding. The market capitalization of Cannabis Bioscience (PK) is $8.31 million. Cannabis Bioscience (PK) has a price to earnings ratio (PE ratio) of 0.00.

CBIH Latest News

Novel Cannabis Patents Livening Up Monday Morning Trading

This firm is looking to leverage cannabinoids’ full potential to improve patient outcomes and contribute to global health initiatives. News of a submission for two patents for cancer care...

FINRA Announces Approval for Corporate Name Change From "China Infrastructure Construction Corp." to "Cannabis Bioscience International Holdings" And Ticker Symbol Change from "CHNC" to "CBIH".

Houston, TX -- August 21, 2023 -- InvestorsHub NewsWire -- Cannabis Bioscience International Holdings (the "Company") a diversified medical and educational company with a particular...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1000.00090.00090.000726644110.0008007CS
4-0.0001-100.0010.00120.000759159500.00091878CS
120.000112.50.00080.0020.00045135766900.00108212CS
260.0003500.00060.0020.000480247720.00106781CS
520.0004800.00050.0020.000355553490.00098289CS
1560.0004800.00050.0020.000355553490.00098289CS
2600.0004800.00050.0020.000355553490.00098289CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
POAIPredictive Oncology Inc
$ 1.95
(82.24%)
139.69M
PBMPsyence Biomedical Ltd
$ 0.6596
(68.52%)
67.11M
SLRXSalarius Pharmaceuticals Inc
$ 3.4299
(60.28%)
18.66M
VKTXViking Therapeutics Inc
$ 66.835
(32.58%)
10.07M
GSHDGoosehead Insurance Inc
$ 86.885
(32.25%)
615.2k
TWOU2U Inc
$ 1.545
(-62.50%)
3.43M
CTNTCheetah Net Supply Chain Service Inc
$ 0.2867
(-40.52%)
4.97M
KDLYKindly MD Inc
$ 1.92
(-40.37%)
563.97k
EZFLEzFill Holdings Inc
$ 4.0383
(-35.13%)
106.87k
SLGLSol Gel Technologies Ltd
$ 0.4494
(-32.93%)
13M
NVDANVIDIA Corporation
$ 114.49
(0.21%)
249.64M
POAIPredictive Oncology Inc
$ 1.95
(82.24%)
139.69M
SLNASelina Hospitality PLC
$ 0.0397
(-13.13%)
137.38M
SQQQProShares UltraPro Short QQQ
$ 9.0599
(-0.00%)
134.54M
PBMPsyence Biomedical Ltd
$ 0.6596
(68.52%)
67.11M

CBIH Discussion

View Posts
Chartmaster Chartmaster 1 week ago
CBIH Pursues Regulatory Compliance and Market Growth with Essential Licensing Applications
GLOBENEWSWIRE 6:00 AM ET 7/15/2024
HOUSTON, July 15, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings(CBIH) has initiated a strategic move to expand its presence in the cannabis market by filing applications for crucial licenses covering the manufacturing, production, and retail components of its cannabis product range.


Preparations are underway for the production and distribution of our products, and continue to foster revenue expansion, which could only be achieved through the practical application of the skills and experiences gained over the past 15 years. Therefore, we are now navigating the licensing phase for our manufacturing units. This involves securing permissions for the production, manufacture and provision of cannabinoid-based items.

Moreover, our firm is deeply invested in maintaining the highest standards of regulatory compliance. In pursuit of this goal, the company has diligently applied for licenses required under Texas state laws, including the Retail Hemp Registration (#8305) from the Texas Department of State Health Services (DSHS), alongside the Initial Food Manufacturer License (#1037264) and Initial Food & Drug Owner application (#1037264).

Amidst ongoing project development and meticulous refinement of patent applications for our formulations and preparing for the development of clinical data trials aimed at validating our products effectiveness, CBIH remains focused on introducing novel revenue-generating avenues through dietary supplements and nutraceuticals. Through a potential strategic alliance with a distinguished national product manufacturer, CBIH looks forward to launching its cannabis-based products to the market for the first time.

"The cannabis industry has encountered major hurdles due to unclear regulations, leading to difficulties for several companies in this sector. Hence, we feel immense pride in our capacity to have been able to withstand the test of time, showcasing our resilience as CBIH seeks to gain a considerable segment of the market and ultimately achieve our pioneering goals. These initiatives collectively function as preparatory measures in light of the prospect of cannabis being reclassified as medicine, propelled by CBIH's competitive drive to spearhead the utilization of this groundbreaking shift," remarks John Jones, CBIH Treasurer and Board Director.

β€œThis has been a journey in the making, and with the successful application of our licenses, we remain committed to strictly adhering to both federal and state regulations and the essence of the law. Our focus is on developing our products as vitamins or nutraceuticals, acknowledging the undeniable therapeutic advantages of cannabis as a form of medicine. At the core of our mission, if our products can offer healing or significantly improve the quality of life for patients, the legality surrounding medical claims becomes secondary. What matters most is harnessing the potential of cannabis compounds to aid those that traditional medicine has forgotten. It is about non-traditional medicine in a traditional world,” says Rosangel Andrades, Research and Development Director.

FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.

For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK

Investor Relations
Peter Nicosia
Bull in Advantage, LLC
Phone: 585-703-6565
Email: Info@BlueHorseshoeStocks.com

Image: https://www.globenewswire.com/newsroom/ti?nf=OTE3NzYwMyM2MzY2MDgzIzIyOTIzMDQ=
Image: https://ml.globenewswire.com/media/NzBhZjhkZGMtNzJjZi00MjM4LWE2MTItZTExZDVlYjNlZGQzLTEzMDM4NTQ=/tiny/CANNABIS-BIOSCIENCE-INTERNATIO.png
Image: Primary Logo

Source: CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.(CBIH)
πŸ‘οΈ0
The Night Stalker The Night Stalker 2 weeks ago
like the pumps here
πŸ‘οΈ0
Chartmaster Chartmaster 2 weeks ago
CBIH: Unleashing the Potential of Cannabis for Tomorrow's Medicine
Newsfile Corp.
Newsfile Corp

A letter from our desk

Houston, Texas--(Newsfile Corp. - July 8, 2024) - Since the start of the year, Cannabis Bioscience International Holdings (OTC Pink: CBIH) has embarked on a transformative journey involving merger opportunities, patent registrations, and company valuation. As we transition into the second half of the year, we aim to address and clarify certain aspects from our previous communications.

From our desks - Rosangel Andrades and Jennifer Salguero.

In the realm of medicine, patent requirements diverge from other forms of intellectual property, as clinical trials or studies are required to substantiate the attributes assigned to a compound.

While CBIH excels in bringing scientific rigor to the table, we acknowledge the imperative need for self-conducted studies. Our strategy unfolds in two primary directions. Initially, to amass comprehensive clinical evidence for our therapeutic interventions. Subsequently, to seize the opportunity presented by the impending declassification of cannabis, making clinical trials a focal point for numerous institutions and pharmaceutical entities. As we brace for the unfolding opportunities post-declassification, CBIH is strategically positioned to lead, thanks to our unique expertise as one of the limited clinical research units specializing exclusively in cannabis, thus, allowing us to generate additional revenues. This distinction would set us apart, given the scarcity of CRUs with comparable experience and understanding of cannabis clinical trials.

Moreover, we advocate for the utilization of provisional patents, which offer a 12-month grace period for conducting the requisite trials. These trials can encompass a variety of methodologies, including in vivo and in vitro preclinical studies, animal model testing, or leveraging single-cell studies.

For more information on single cells studies, please visit: drive.google.com/file/d/1yuCVocWQqq1B6EqN1G5jlzy8g8LGuQSC/view?usp=sharing

Furthermore, we intend to file all our patents with the United States Patent and Trademark Office (USPTO), targeting the lucrative U.S. market. This strategic filing not only strengthens our presence in the industry but also paves the way for collaborations with pharmaceutical companies exploring the potential of cannabinoid compounds. Our patent assets are poised to become a significant source of revenue. It's noteworthy that a 2019 Statista report indicated AbbVie's dominance with 59 cannabis patents, compared to Pfizer's 25. Given Pfizer's track record of striving for industry leadership, it's conceivable that they would be motivated to acquire more cannabis patents to assert their dominance in this emerging field.

In consequence, our objective is to tackle diseases that have been consistently overlooked and face a scarcity of effective treatments, such as menopause syndrome that could affect quite literally any woman in their lifespan, and Ewing cancer which is a severe and devastating condition that affects bones and soft tissue in adolescents. Our team is committed to addressing those neglected by conventional medical research.

From my desk - John Jones.

Evaluating our company's worth was a crucial move for our company, especially in light of potential merger and acquisition discussions. Identifying the right partner for such a significant endeavor remains our priority. Our goal transcends mere transactions; we seek a mutually beneficial partnership that thrives over time, making the selection of the perfect collaborator our greatest challenge. Moreover, achieving a valuation of $2 billion is no small feat, it is a testament to the hard work, dedication, and innovative spirit of our team.

Our agreement with VITA Biotech Research has facilitated the receipt of the second installment of $50,000 for CBIH, catalyzing advancements in the marketing and development of our nutraceuticals.

Additionally, this partnership has facilitated our ability to register trademarks for our product names, which will be sold as dietary supplements, nutraceuticals, or vitamins, adhering to local regulations. This strategic move holds significant value for our company, as certain vitamins, such as our Cancer VITA or Precancer VITA, could exert a remarkable influence if they gain distribution through retailers like Walmart or Walgreens. This highlights the critical importance of differentiating our products from those of competitors by trademarks.

Initiatives like this infuse the company with a fresh and profound value. Conversely, a firm that disregards patenting, omits trademarking, dismisses valuation, and fails to form elite distributor partnerships essentially loses its worth. Therefore, every step taken, every seed planted, dramatically elevates the company's value.

As CBIH continues to expand, we remain committed to investing time, effort, and thoughtful consideration into our endeavors that ultimately transform into revenues, predominantly because we cannot be a company that can't see the forest from the tree. Instead, we are gaining sustainable competitive advantage in the industry.

Each step we undertake lays the groundwork for future successes, mirroring the trajectory of companies that have transformed from modest beginnings to industry leaders. We are poised for a prosperous future, driven by various revenue generation centers, strategic partnerships, and continued growth.

FORWARD-LOOKING STATEMENTSThis press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.

For more information contact us at:(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK

Investor Relations:
East Coast
Peter Nicosia
Bull in Advantage, LLC
Phone: 585-703-6565
Email: Info@BlueHorseshoeStocks.com

West Coast
Zach Logan
Pacific Capital Markets LLC
Phone: 858.864.0011
Email: pacificcapitalmarketsllc@gmail.com

https://images.newsfilecorp.com/files/10188/215666_012882b504f37b28_logo.jpg

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/215666

SOURCE Cannabis Bioscience International Holdings

https://api.newsfilecorp.com/newsinfo/215666/130
https://www.otcmarkets.com/stock/CBIH/news/story?e&id=2910920
πŸ‘οΈ0
The Night Stalker The Night Stalker 3 weeks ago
https://stockcharts.com/h-sc/ui?s=cbih&p=W&yr=1&mn=6&dy=0&id=p24986097784&listNum=23&a=1113701411
πŸ‘οΈ0
The Night Stalker The Night Stalker 3 weeks ago
https://stockcharts.com/h-sc/ui?s=cbih&p=W&yr=1&mn=6&dy=0&id=p24986097784&listNum=23&a=1113701411
πŸ‘οΈ0
ChowChowDog ChowChowDog 3 weeks ago
ONLY 1 more?

Why only 1 more?
πŸ‘οΈ0
The Night Stalker The Night Stalker 3 weeks ago
1 more pump brewing
πŸ‘οΈ0
Chartmaster Chartmaster 3 weeks ago
CBIH advances Cancer Care with Novel Cannabis Patents for Breast and Pancreatic Cancers

HOUSTON, July 01, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is excited to announce the submission of our inaugural pair of patents, focusing on novel treatment methodologies for breast and pancreatic cancers, for legal review and subsequent registration.

Our dedicated scientific team has invested countless hours in research, culminating in the development of innovative treatment approaches specifically designed to tackle breast and pancreatic cancers. These conditions, affecting millions globally, present unique challenges due to their prevalence and the severity of their outcomes. Breast cancer, for instance, impacts approximately one in eight women in the United States over their lifetime, while pancreatic cancer is notorious for its late-stage diagnosis and grim prognosis, with a five-year survival rate below 10%.

Jennifer Salguero, PhD in Science with emphasis on Microbiology, highlights the urgency and strategic focus of our approach: "Given the stark statistics associated with these cancers, our team recognizes the critical need for aggressive yet targeted interventions. Our aim is to not only target the tumors but also safeguard surrounding tissues, leveraging the inherent antitumor properties of cannabinoids."

CBIH aims to accelerate our pace of innovation by submitting an additional 3 to 4 patents per month throughout the remainder of the year. Among our top priorities are patents related to the treatment of herpes zoster, knee osteoarthritis, and Alzheimer's disease, harnessing the antiviral, anti-inflammatory, and neuroprotective benefits of cannabinoids.

To support this goal, we are expanding and strengthening our research team, focusing on patent and formulation development. We are honored to welcome Sheila Tarqui, with a comprehensive background in biology, pharmaceutical chemistry, public health, and dermatic cosmetics, enriched by her education from Ricardo Palma University, MarΓ­a Auxiliadora University, San Juan Bautista Private University (Peru), and Francisco de Vitoria University (Madrid, EspaΓ±a), makes her an invaluable addition. We expect Tarqui’s expertise will significantly contribute to advancing our innovation and maintaining our high standards of excellence.

Moreover, we are proactively trying to recruit medical specialists in oncology and cardiology to deepen our exploration of cannabis compounds' therapeutic applications. Despite substantial existing research, cardiovascular diseases persist as the world's leading cause of death, with limited understanding of cannabinoids' potential in this field. Identifying this as an emerging opportunity, we see the combination of cardiovascular medicine and cannabinoid research as a promising path for developing innovative treatments. Our recruitment efforts aim to fill this knowledge gap and unlock new possibilities for addressing prevalent and life-threatening conditions worldwide.

"These strategies contribute to securing and protecting our intellectual property which is paramount. By harnessing cutting-edge therapies, artificial intelligence, and advanced biotechnological techniques, we aim to safeguard and successfully market our groundbreaking medical advancements" says Rosangel Andrades, Research and Development Department Director.

We remain steadfast in our mission to leverage the full potential of cannabinoids to improve patient outcomes and contribute to global health initiatives. At CBIH, we are redefining medicine and treatment strategies.

FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.

For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK

Investor Relations:
East Coast
Peter Nicosia
Bull in Advantage, LLC
Phone: 585-703-6565
Email: Info@BlueHorseshoeStocks.com

West Coast
Zach Logan
Pacific Capital Markets LLC
Phone: 858.864.0011
Email: pacificcapitalmarketsllc@gmail.com
https://www.globenewswire.com/newsroom/ti?nf=OTE3MTQzNCM2MzQ4NzkyIzIyOTIzMDQ=
https://ml.globenewswire.com/media/NjJhZDk4NzYtYmVhMy00ODZhLTk5NTQtNGQ2OTIyOTRkYTA2LTEzMDM4NTQ=/tiny/CANNABIS-BIOSCIENCE-INTERNATIO.png

Source: CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.

© 2024 GlobeNewswire, Inc.
https://www.otcmarkets.com/stock/CBIH/news/story?e&id=2905906
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 month ago
u sell for loss
πŸ‘οΈ0
Rainer Rainer 1 month ago
CBIH's Recently Appointed Director Unveils Groundbreaking Product Strategies and Potential Partnership with Industry Leader

As CBIH prepares for the manufacturing and distribution of its products, the potential collaboration might involve this entity acting as CBIH's product…— CBIH (@CBIHstock) June 24, 2024
πŸ‘οΈ0
PINKPASTE PINKPASTE 1 month ago
Basing around .0011? But it's worth BILLIONS.lol
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 month ago
basing
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 month ago
https://www.stockscores.com/charts/charts/?ticker=cbih
πŸ‘οΈ0
The Night Stalker The Night Stalker 1 month ago
https://stockcharts.com/h-sc/ui?s=cbih&p=W&yr=1&mn=6&dy=0&id=p24986097784&listNum=23&a=1113701411
πŸ‘οΈ0
BuckBuckBuck BuckBuckBuck 1 month ago
When will this GIANT climb?
πŸ‘οΈ0
hans1111 hans1111 1 month ago
With the latest news shareprize estimation around $0,20 p.s.
👍️ 1
HNDRXX HNDRXX 1 month ago
Big breakout coming
πŸ‘οΈ0
Tradesmart7 Tradesmart7 1 month ago
$CBIH Bought some here for a Momentum runner here. $2 Billion News evaluation with Mark Cubans brother on the board.
👍️ 1
Tradesmart7 Tradesmart7 1 month ago
$CBIH Bought some here for a Momentum runner here. $2 Billion News evaluation with Mark Cubans brother on the board.
👍️ 1
Viewmont Viewmont 1 month ago
$CBIH Excellent day!
πŸ‘οΈ0
Viewmont Viewmont 1 month ago
$CBIH Excellent day!
πŸ‘οΈ0
Chartmaster Chartmaster 1 month ago
At 18's now, the HOD, way undervalued and market seems to be sleeping on it, word is slowly spreading though
💩 1 🤡 1
okwife okwife 1 month ago
$CBIH$$$$ AT .0013 VALUE IS ONLY $14.3MILLION A FAR CRY
FROM $2BILLION VALUE THAT REPORT SUGGESTS.
https://www.otcmarkets.com/stock/CBIH/security
MY MATH SAYS .181818
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174610441
👍️ 1
Chartmaster Chartmaster 1 month ago
IDK, but the chart was telling me a breakout over 8's was imminent, see my post a couple weeks ago, chart said to me something was stirring and now today the breakout on the news, charts forcast news events, proven here.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174546410
πŸ‘οΈ0
ANTI-BAGHOLDER ANTI-BAGHOLDER 1 month ago
The only way β€œthe chart” would know is if someone knew news was coming…

Unless that’s exactly what you are referring too?
πŸ‘οΈ0
Chartmaster Chartmaster 1 month ago
Yeah, the chart saw it coming, that's why I bought, from the chart, not the news
πŸ‘οΈ0
ANTI-BAGHOLDER ANTI-BAGHOLDER 1 month ago
How does a chart win here? It needed some insanely stupid news for it to move.
πŸ‘οΈ0
Chartmaster Chartmaster 1 month ago
Here's the breakout I called for! Another chart win!!!
πŸ‘οΈ0
EyeInTheSky EyeInTheSky 1 month ago
massive
πŸ‘οΈ0
Chartmaster Chartmaster 1 month ago
CBIH Achieves $2 Billion Valuation Following StoneBridge Advisory Assessment
Newsfile Corp.
Newsfile Corp

Houston, Texas--(Newsfile Corp. - June 17, 2024) - Cannabis Bioscience International Holdings (OTC PINK: CBIH) has been valued at $2 Billion following a rigorous evaluation by StoneBridge Advisory, a leading financial advisory firm based in Los Angeles, California.

StoneBridge's assessment highlights CBIH's formidable market presence, cutting-edge product offerings, and solid business framework. Moreover, this valuation serves as a testament to investor and analyst optimism regarding CBIH's capacity for sustained growth and expansion.

The valuation was reached through a comprehensive review of CBIH's financial metrics, market penetration, industry competition, and strategic planning. Additionally, it took into account the exceptional skill sets within the company. Including securities attorney; corporate attorney, patent attorney, in-house counsel, comptroller with a Magister Scientiarum in Administration, CPA, PCAOB, graphic designer, Master's Degree in Audiovisual Communication and Advertising Content, Ph.D.-level scientists with emphasis on microbiology, medical professionals certified in cancer biology, peritoneal dialysis, pregnancy-related emergency care, as well as board-certified in General medicine and internal medicine, Anti-aging medicine Specialist, Master of Health Care Administration, and Doctorate in Dental Surgery. These experts have contributed to the development of a diversified portfolio of innovative therapies and medical solutions over the past 15 years. Their work addresses gaps in conventional treatments, and provides natural alternatives for widespread health issues globally.

StoneBridge Advisory employed meticulous due diligence and sophisticated financial modeling during the valuation process to guarantee precision and accurately represent the value of CBIH.

John Jones, Treasurer and Director of CBIH, commented on the significance of this valuation, stating: "We have been meticulously reconstructing our company and reinforcing its foundations. Given the promising opportunities we've identified, obtaining a valuation became the next logical step to gauge our progress and plan for future growth." He further noted, "Being positioned in rapidly evolving sectors like medical cannabis, clinical research, and biotechnology, coupled with our unparalleled expertise, positions us uniquely to seize advantageous opportunities that will benefit both our company and shareholders."

This landmark $2 Billion valuation positions CBIH among an elite group of startups and fresher/emerging companies that have achieved such a notable feat. This milestone paves the way for CBIH to pursue strategic alliances, investment opportunities, and ambitious expansion strategies, further cementing its status as a leader in the cannabis bioscience sector.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.

For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK

Investor Relations:

East Coast

Peter Nicosia
Bull in Advantage, LLC
Phone: 585-703-6565
Email: Info@BlueHorseshoeStocks.com

West Coast

Zach Logan
Pacific Capital Markets LLC
Phone: 858.864.0011
Email: pacificcapitalmarketsllc@gmail.com

https://images.newsfilecorp.com/files/10188/213088_b92b11ca44633888_logo.jpg

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/213088

SOURCE Cannabis Bioscience International Holdings

https://api.newsfilecorp.com/newsinfo/213088/130
https://www.otcmarkets.com/stock/CBIH/news/story?e&id=2892259
πŸ‘οΈ0
Demogod1 Demogod1 1 month ago
Hey scammer, haven't heard here from you much lately, wonder why

Not to mention the ENDV & MIKP boards..yo where you hiding at? Come face the music Oh, and I'm not a disgruntled "investor" so you can stop floating that narrative. I wouldn't dump a cent into your POS stocks. Just well aware of you & what you & that sh_t-bag Leupold do..
πŸ‘οΈ0
Demogod1 Demogod1 1 month ago
Much truth, bro. Thanks for that

..that part about his son, I'd never heard before. That's going in a dark place right there, damn.. 😣 ruthless, even in my book

He is an utter POS tho, right about that imo. No tears shed for him

Hey, DM me on ST (can't DM here, I'm a freeloader)? ..Interested in comparing a few notes on that operation. Demogod1 on there, too..
πŸ‘οΈ0
Demogod1 Demogod1 1 month ago
😆 haha, this is how ppl react when they realize the truth of the matter is they pissed-away everything on a(n obvious & poorly executed) scam!

Projection.. I mean there's no way around it: You've apparently been scammed.

Call me an idiot for providing the evidence tho
πŸ‘οΈ0
Viewmont Viewmont 1 month ago
What an f'n idiot! You're blocked!
πŸ‘οΈ0
Demogod1 Demogod1 2 months ago
Um ya...bout that..

http://stocktwits.com/Demogod1/message/575849470

..this is pretty concerning tb perfectly h
πŸ‘οΈ0
Viewmont Viewmont 2 months ago
$CBIH Check it out! https://www.vitabiotech.in/
Vita Biotech Retains CBIH Services for Clinical Studies
"Vita Biotech will act as a financial subsidiary and catalyst for CBIH's data collection trials"
πŸ‘οΈ0
Viewmont Viewmont 2 months ago
$CBIH Great News! https://www.newsfilecorp.com/release/211751/Vita-Biotech-Retains-CBIH-Services-for-Clinical-Studies
πŸ‘οΈ0
Chartmaster Chartmaster 2 months ago
Breakout over 8's appears imminent!
πŸ‘οΈ0
Chartmaster Chartmaster 2 months ago
Vita Biotech Retains CBIH Services for Clinical Studies
Newsfile Corp.
Newsfile Corp

Houston, Texas--(Newsfile Corp. - June 5, 2024) - Vita Biotech Research has entered into a significant partnership with Cannabis Bioscience International Holdings (OTC Pink: CBIH), to fund the clinical data collection efforts of CBIH's rigorous data clinical studies, underscoring Vita Biotech's commitment to supporting cutting-edge research and ensuring the highest standards of clinical data integrity.

Through this strategic alliance, Vita Biotech will act as a financial subsidiary and catalyst for CBIH's data collection trials, a vital phase in evaluating the efficacy and safety of its formulations before they reach the market. This accelerated funding is expected to speed up CBIH's progress toward its scientific and commercial goals.

Furthermore, this collaboration allows CBIH to chart a course of its reconstruction process as it facilitates to isolate each medical formulation into a unique legal entity. This risk management strategy aligns with industry practices aimed at simplifying financing and partnerships, streamlining intellectual property and licensing processes.

The choice of Texas as the jurisdiction for patent housing is driven by its business-friendly environment, including favorable judicial precedents, cost-effective litigation, and access to federal courts adept in handling complex cases. Therefore, this calculated maneuver would place CBIH in a strong defensive posture in the event of legal challenges, and it is foreseen to lessen potential legal liabilities of the parent corporation.

The decision to proceed with this collaboration followed medical legal standards to mitigate any potential medical conflicts arising from the studies, upholding ethical standards to maintain credibility and executing CBIH's protocols effectively, which could lead to improved statistical significance.

"The nature of clinical trials and data collection necessitates a cooperative endeavor between different entities, each bringing unique advantages to the table, without compromising the integrity and safety of data management during the trials. This way we take a significant leap forward in both organizations' missions and the enhancement of patient care," says Dr. Jennifer Salguero, PhD in Science specialized in Microbiology from SΓ£o Paulo Brazil University, and VITA's Director of Clinical Trial Operations.

Overall, this partnership offers a platform for funding CBIH's projects, safeguards both parties from risks related to intellectual property and litigation, and ensures the meticulous and ethical collection of data. CBIH and Vita Biotech look forward to potentially bolster the credibility of our research among leading pharmaceutical companies, paving the way as pioneers in medical cannabis clinical research.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.

For more information contact us at:(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstockInstagram: www.instagram.com/CBIHSTOCK

Investor Relations:
East Coast
Peter Nicosia
Bull in Advantage, LLC
Phone: 585-703-6565
Email: Info@BlueHorseshoeStocks.com

West Coast
Zach Logan
Pacific Capital Markets LLC
Phone: 858.864.0011
Email: pacificcapitalmarketsllc@gmail.com

https://images.newsfilecorp.com/files/10188/211751_687e9dd4b440484c_logo.jpg

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/211751

SOURCE Cannabis Bioscience International Holdings

https://api.newsfilecorp.com/newsinfo/211751/130
https://www.otcmarkets.com/stock/CBIH/news/story?e&id=2882133
πŸ‘οΈ0
Nikodemos Nikodemos 2 months ago
Don't trust this MORON! Check out his socials & you'll find he runs a SCAM OPERATION, takes shares from companies in exchange for payment: & THEN fake-PUMPS the stocks so he & his buddy Shane Leopold can LIQUIDATE into the unsuspecting!!

This CLOWNSTICK (Jeff Lien) is a POS...

He claimed BRINGING AN ARMY (on his socials) in another stock!!

And is engineering a REVERSE SPLIT so he can clear & liquidate the shares he was paid by the MORON ceo Mark B. Newbauer.

Should they FOLLOW with the R/S I'm going to make sure the SEC/FINRA & other U.S. agencies (this CLOWN Jeff Lien is listed as a REALTOR in Canada & CLEARLY not a successful one: So he trolls the board, claiming he runs a MARKETING company, buying FOLLOWERS across his social platforms & SCAMMING on his DISCORD!! He is a WORLD CLASS POS -- no wonder he lost his son! Prolly a SHIT dad letting his kid get addicted to OPIODS -- he should OFF HIMSELF - imho & make the world a better place. Instead he TROLLS the OTC & preys on the unsuspecting)


PS: NONE of this is unknown information. Do DD on these CornerstoneMarketing CLOWNSTICKS & you'll discover EVERYTHING for yourself... And since they DO NOT OPENLY DISCLOSE being PAID TO PUMP!! I decided I'd share & help people AVOID whatever this SHITSTAINS are pumping/selling.

Because they are NO GOOD at it & have supported one R/S after another!! Essentially WIPING shareholder out!! Investors BEWARE!


Anyone on this board reading this: CONSIDER YOURSELF WARNED!!




JUST THE FACTS PLEASE!!


....




...




..



.
πŸ‘οΈ0
Viewmont Viewmont 4 months ago
$CBIH Price is cheap and holding up! Potential Merger was announced earlier, when that happens CBIH will be flying up real high! https://www.cbih.net/
πŸ‘οΈ0
Viewmont Viewmont 4 months ago
BUSINESS DESCRIPTION
The company is dedicated to providing services in all therapeutic areas of clinical research through one of our products: Alpha Research Institute, LLC. a Houston-based Research Unit that offers phase I to phase IV Clinical Research Studies. The Company also operates an international learning platform that provides knowledge about cannabinoids' medical benefits: Pharmacology University. We have been researching medical cannabis uses for more than 15 years, as a result, we have published ebooks, audiobooks, videos, and magazines. Cannabis Bioscience International Holdings will unite both experiences, clinical studies, and knowledge about cannabinoids.
πŸ‘οΈ0
Viewmont Viewmont 4 months ago
It's holding up!
πŸ‘οΈ0
Viewmont Viewmont 4 months ago
CBIH I've seen this climb, when it climbs it'll go high!
πŸ‘οΈ0
Viewmont Viewmont 4 months ago
Please be patient. The last couple of days we did nothing but to water the plant, we are under a couple of non circumvent / non disclosure agreements, thank you for your interest. pic.twitter.com/I409GJKzTx— CBIH (@CBIHstock) March 14, 2024
πŸ‘οΈ0
Chartmaster Chartmaster 4 months ago
Bought 11's here today!
πŸ‘οΈ0
Xunefox Xunefox 4 months ago
Interesting trades
πŸ‘οΈ0
Viewmont Viewmont 4 months ago
$CBIH Nice day! Merger and other excellent news are incoming!
πŸ‘οΈ0
Viewmont Viewmont 4 months ago
$CBIH Blessed to be part of the greatest medical cannabis company on the OTCMKTS $CBIH - synonym of the future of cannabis medicine https://t.co/Wr3n9RlXD3— CBIH (@CBIHstock) March 10, 2024
πŸ‘οΈ0
Viewmont Viewmont 5 months ago
https://images.newsfilecorp.com/files/10188/200651_4d07a35ae47b5919_001full.jpg
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock